http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2578428-C1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2610bfe1bc6420e762e855041ce963d8
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N21-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-49
filingDate 2015-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2016-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_03afa50e436ede49e23906c479ad54f8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8419c3ae49c65aac4eadc5ecef56c58b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1356f3dc05b8a35c9b820c680f9aae06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0c1cdb937a7fcce9567edc62a098dfa3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_063416a37c24aa1b0ed46112fc033fbe
publicationDate 2016-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber RU-2578428-C1
titleOfInvention Method for rapid diagnosis of resistance and susceptibility to acetylsalicylic acid
abstract FIELD: medicine. n SUBSTANCE: invention can be used for rapid diagnosis of resistance and sensitivity to acetylsalicylic acid (ASA). For this blood sampling is performed in the patient prior antiplatelet therapy. As used anticoagulant 3.2% sodium citrate, 0.5 ml of blood was placed into test cuvette, the blood sample is passed through a short, of the order of 10 -5 with a current pulse with registration function decline polarization of the sample, and then perform the Fourier transform of this function and parameters are calculated impedance locus in the frequency range 0.1-125 kHz using a dielectric Fourier spectrometer. For values of the reference interval r0=4.518-4.551, x0=1.925-1.939, y0=-1.395--1.385 diagnose sensitivity, while values of r0=4.504-4.517, x0=1.914-1.926, y0=-1.384--1.375 - resistance to acetylsalicylic acid. n EFFECT: invention makes it possible to quickly and reliably carry out the diagnosis of resistance to ASA in a patient prior to treatment that will prevent the development of unwanted coronary events in patients with coronary artery disease. n 1 cl, 2 dwg, 2 tbl, 2 ex
priorityDate 2015-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2413953-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2379684-C2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010039992-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2244
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419527521
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6022
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419556224
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6224
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCO01945
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID409206349

Total number of triples: 26.